Courier Health, a New York-based healthcare technology company that builds software to help biopharmaceutical organizations improve the patient experience, raised $50 mn in a Series B round led by Oak HC/FT, with continued backing from Norwest and Work-Bench.
The company will use the capital to expand product capabilities and strengthen its position in managing patient experiences across the life sciences sector.
Courier Health purpose-built customer relationship management (CRM) platform enables life sciences teams to manage, analyze, and optimize the entire patient journey – from diagnosis to therapy adherence.
In July 2024, Courier Health raised $16.5 mn in Series A funding led by Norwest Venture Partners with participation from Work-Bench. The investment supports engineering and sales expansion as well as further platform innovation to meet rising demand for patient-centric CRM solutions in biopharma.
Biopharma companies continue to face fragmented patient engagement despite advances in treatment development. Disconnected data systems and limited coordination across stakeholders create gaps between prescribed therapies and patient adherence.
According to Beinsure analysts, these inefficiencies reduce treatment effectiveness and increase operational complexity across patient support programmes.
Courier Health addresses this issue through a platform designed to connect data sources and coordinate patient journeys.
The system applies artificial intelligence to identify at-risk patients and generate insights that support intervention strategies. This approach enables a more consistent experience from initial education through long-term therapy management.
The platform integrates data across providers, pharmacies, and internal systems while supporting workflow automation.
AI-driven processes handle routine tasks, allowing teams to focus on higher-value activities. Market access teams gain visibility into patient engagement, improving coordination and response times across the network.
Danny Sigurdson said the company focuses on simplifying complex medical journeys through structured technology. He added that the partnership with Oak HC/FT provides capital to scale both the platform and its AI capabilities while expanding the team to support customers more effectively.
Billy Deitch said the sector has lacked a dedicated platform for managing patient engagement at scale. He pointed to Courier Health’s infrastructure and applied AI strategy as factors driving adoption among biopharma companies.
The funding follows a period of rapid growth for the New York-based company. In 2025, Courier Health increased the number of customers and therapies supported on its platform by more than 400%.
The company also expanded its workforce significantly to meet rising demand.
The new capital will support continued hiring and product development as the company expands its reach across the biopharma market. Courier Health aims to scale its platform to support a broader set of organisations seeking structured, data-driven approaches to patient engagement.
Courier Health’s mission is to reinvent how people living with chronic and rare diseases are supported. Its SaaS platform provides a secure, HIPAA-compliant “command center” where biopharma commercial, patient-services, and access teams can coordinate activities, automate workflows, and gain a 360-degree view of patient progress.
By connecting disparate datasets, it helps ensure that patients start and stay on prescribed therapies, reducing time-to-start by up to 67% and improving adherence rates
